Overview

Study of AERAS 422 in Healthy Adults

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and immunogenicity of AERAS-422 in healthy, BCG-naïve adults.
Phase:
Phase 1
Details
Lead Sponsor:
Aeras
Treatments:
BCG Vaccine